Physician profile
Christopher Jordan
NPI 1679523625
$5,125.93
in general payments reported to CMS, 2019-2025
46 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,074 · 2020: $682 · 2021: $582 · 2022: $568 · 2023: $874 · 2024: $190 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856 · Education: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $856.14 |
| Education | $363.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,867.06 | 2019 | |
| Astellas Pharma US INC | $349.98 | 2020-2025 | Xtandi, Padcev |
| Astrazeneca Pharmaceuticals LP | $296.01 | 2020-2023 | Lynparza |
| Janssen Biotech, INC. | $286.20 | 2022-2025 | Darzalex, Erleada, Imbruvica |
| Puma Biotechnology, INC. | $277.53 | 2019-2025 | |
| Amgen INC. | $219.12 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $174.91 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $162.17 | 2019-2024 | Opdualag, Opdivo |
| Rigel Pharmaceuticals, INC. | $157.78 | 2020-2024 | Tavalisse, Rezlidhia |
| Regeneron Healthcare Solutions, INC. | $157.56 | 2020-2024 | Libtayo |
| Genentech USA, INC. | $89.66 | 2019-2023 | Venclexta |
| Dova Pharmaceuticals | $83.71 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $83.36 | 2020-2025 | |
| Celgene Corporation | $82.55 | 2022 | |
| Incyte Corporation | $51.46 | 2020-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.